Jacqueline Vuong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacqueline Vuong has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Avinainder Singh
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - Sharmila Dorbala
Brigham and Women’s Hospital
2 shared publications - Sophia Jacob
Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA
2 shared publications - Akshay S. Desai
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication - Allison C. Ostriker
Yale Cardiovascular Research Center, Vascular Biology and Therapeutics Program, and Departments of Medicine and Pharmacology, Yale University School of Medicine, New Haven, CT 06511, USA
1 shared publication Amy Pan
Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
1 shared publication
Latest Publications
- 13 February 2020
- Published by Taylor & Francis in Amyloid
- Vol. 27 (3) , 210-212
Geographic variation in public interest about amyloidosis in the United States and English speaking countries
(2020). Geographic variation in public interest about amyloidosis in the United States and English speaking countries. Amyloid. Ahead of Print.
- 13 February 2020
- Published by Taylor & Francis in Amyloid
- Vol. 27 (3) , 210-212
Geographic variation in public interest about amyloidosis in the United States and English speaking countries
(2020). Geographic variation in public interest about amyloidosis in the United States and English speaking countries. Amyloid. Ahead of Print.
- 1 February 2019
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 25 (2) , 125-129
Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016
- 1 February 2019
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 25 (2) , 125-129
Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016
- Open Access
- 7 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198700
Intranasal delivery of VEGF enhances compensatory lung growth in mice
Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5–50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.
- 7 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198700
Open AccessIntranasal delivery of VEGF enhances compensatory lung growth in mice
Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5–50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.
- Top Cited Papers
- 24 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 355 (6327) , 842-847
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Faulty blood cells and heart disease: Recent studies have shown that elderly people's blood cells often harbor mutations in genes encoding certain epigenetic regulators. These mutations can lead to clonal expansion of the mutant blood cells, which increases the risk of blood cancers and cardiovascular disease. Fuster et al. generated a mouse model to investigate how one of these genes, Tet2 , affects atherosclerosis development (see the Perspective by Zhu et al. ). They found that the disease progressed more rapidly in mice transplanted with Tet2 -deficient bone marrow cells. This was due to increased secretion of interleukin-1β by Tet2 -deficient macrophages in a process that depended on the action of inflammasomes. Science , this issue p. 842 ; see also p. 798
- 24 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 355 (6327) , 842-847
Top Cited PapersClonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Faulty blood cells and heart disease: Recent studies have shown that elderly people's blood cells often harbor mutations in genes encoding certain epigenetic regulators. These mutations can lead to clonal expansion of the mutant blood cells, which increases the risk of blood cancers and cardiovascular disease. Fuster et al. generated a mouse model to investigate how one of these genes, Tet2 , affects atherosclerosis development (see the Perspective by Zhu et al. ). They found that the disease progressed more rapidly in mice transplanted with Tet2 -deficient bone marrow cells. This was due to increased secretion of interleukin-1β by Tet2 -deficient macrophages in a process that depended on the action of inflammasomes. Science , this issue p. 842 ; see also p. 798